Oxford Technology 2 VCT raised £6.0m in 2000 with top-up offers to date raising a further £468k. The Fund is now fully invested.
Click here to view the OT2 Interim Accounts 2022
Dividends paid to 28 Feb 2022 total 22.5p per share, mainly resulting from the sale of Hardide Ltd, Commerce Decisions and OC Robotics.
The Oxford Technology VCTs have now merged into OT2 VCT and Oxford Technology 2 VCT PLC has also launched an offer for subscription of new Leisure Shares. The RNS can be read here
View Documents Relevant to Merger and Offer
The Key Information Document for OT2 VCT is available here: OT2 KID
New articles have been adopted OT2 VCT - they can be seen here: Articles 2021
|Arecor- Investment Information for OT2|
|Date of First Investment||Jul 2007|
|Arecor - Investment Information for OT3|
|Date of First Investment||Jul 2007|
|Arecor - Investment Information for OT4|
|Date of First Investment||Jul 2007|
Arecor Limited became Arecor Therapeutics Plc and floated in June 2021. It is a leader in the development of innovative formulation technology that enables differentiated biopharmaceutical products. It has developed a proprietary, patent backed formulation technology platform that has been proven to stabilize a broad range of molecules as aqueous compositions. Many proteins, peptides and vaccines are too unstable in liquid form and/or at high concentrations to develop stable ready-to-use drugs and Arecor has overcome these challenges to significantly enhance the delivery of therapeutic medicines to patients. Since inception in 2007, it has built a successful revenue generating business employing this technology to enable and differentiate biopharmaceuticals for a large cross section of the major pharmaceutical companies on a fee for service plus licensing model.
Arecor has taken the strategic decision to develop a portfolio of differentiated peptides through to clinical proof of concept, with an initial focus on diabetes as a therapeutic area. Arecor have announced three key products: an ultra-rapid acting insulin, a highly concentrated insulin and a stable aqueous glucagon. Arecor has successfully defended two key European patents against active opposition which is an indicator of both the novelty of their work and the importance to potential competitors. Innovate UK backed the development of the super-fast-acting prandial insulin with a £500k grant. Arecor is based at the Cambridge Science Park in the UK and has a highly talented scientific and management team.
Since inception in 2007, it has built a successful revenue generating business employing this technology to enable and differentiate biopharmaceuticals for a large cross section of the major pharmaceutical companies on a fee for service plus licensing model. Arecor has taken the strategic decision to develop a portfolio of differentiated peptides through to clinical proof of concept, with an initial focus on diabetes as a therapeutic area. Arecor have announced three key products: an ultra-rapid acting insulin, a highly concentrated insulin and a stable aqueous glucagon.
Arecor has successfully defended two key European patents against active opposition which is an indicator of both the novelty of their work and the importance to potential competitors. Innovate UK backed the development of the super-fast-acting prandial insulin with a £500k grant.
Arecor is based at the Cambridge Science Park in the UK and has a highly talented scientific and management team.
|ImmunoBiology- Investment Information for OT2|
|Date of First Investment||Dec 2000|
|ImmunoBiology- Investment Information for OT3|
|Date of First Investment||May 2003|
|ImmunoBiology- Investment Information for OT4|
|Date of First Investment||Oct 2005|
ImmBio was founded in 2003 by Camilo Colaco to develop vaccines that engage dendritic cells. Dr. Colaco identified the role that Heat Shock Proteins play in activating the immune system. The company has programmes developing vaccines against Tuberculosis, Meningitis and Pneumonia. The TB and Meningitis vaccines have been partnered for development in China and India.
The pneumonia product PnuBioVax has now been trialled on humans in a Phase 1 trial which primarily and successfully assessed safety of the approach. The study showed the vaccine creates antibodies against a wide range of strains. The company has signed its first license deal for PnuBioVax with CNBG – China National Biotec Group – part of the state owned Sinopharm group. The license is for the development of a vaccine for infants in the Chinese market.
Pneumonia produces greater infant mortality than TB, HIV and malaria combined. There are approximately 100 serotypes (variants) of Streptococcus pneumoniae in circulation. The emergence of new serotypes presents an ongoing challenge. Existing marketed vaccines are relatively expensive to produce and do not cover all existing or emerging strains. Also, they do not produce good resistance in children, one of the primary patient groups. In contrast, PnuBioVax offers the potential of improved protective breadth and low production costs.
PnuBioVax not only protects against a larger number of strains, it also provides protection against the toxins produced by the bacteria.
|Inaplex- Investment Information for OT2|
|Date of First Investment||Sept 2001|
|Inaplex- Investment Information for OT3|
|Date of First Investment||Mar 2003|
InaPlex is a specialist in CRM integration. Customer Relationship Management systems are used by organisations to manage and foster their relationships with customers. Over the last 10 years, they have grown in importance and sophistication; they are now a major line of business application for many organisations. Merging CRM systems when organisations merge is far from trivial. Inaplex is now based in California.
|Insense - Investment Information for OT2|
|Date of First Investment||Jun 2001|
|Insense - Investment Information for OT3|
|Date of First Investment||May 2003|
|Insense - Investment Information for OT4|
|Date of First Investment||April 2005|
Insense Ltd is a spin-out from Unilever an developed a range of active dressings, which can be applied to the skin to treat a variety of conditions.
In order to sterilise the Insense dressings after manufacture, Professor Davis had to develop a method of stabilising the proteins so that they would withstand ionising radiation. Having done this, it transpired that many pharma companies were interested in using this technology for their own protein-based products. This led to the spin-out of Arecor. All the shareholders in Insense received the same % of shares in Arecor which then raised capital to fund its own expansion. Arecor is making excellent progress.
Insense is now developing a potential treatment for fungal nail and through Microarray it is developing a technology to diagnose the state of a wound, in order to apply the most suitable dressing.
|Oxis Energy - Investment Information for OT2|
|Date of First Investment||Jan 2000|
|Oxis Energy - Investment Information for OT4|
|Date of First Investment||Nov 2005|
Oxis Energy is developing a rechargeable battery with the following exceptional properties:
- Extremely high specific energy density 1.5-2x existing best rechargeable battery
- Wide temperature of operation 0°C to 125°C
- Inherent safety - no control electronics
These properties represent a step change in performance versus existing rechargeable battery technologies and for some markets they will be a key enabling technology, for example, the energy weight ratio specific energy density is pivotal in electric vehicles because the weight of the battery is a significant part of the total vehicle weight.
Commercially, the company is currently focused on three key markets, down-hole oil/gas tools, electric vehicles and power tools. The oil/gas industry currently spends in excess of $100m/year in primary batteries (one time use) in downhole tools.
Oxis ability to operate in a high temperature range and its inherent tolerance to high charge/discharge are critical advantages ' and of course there is significant value because one rechargeable cell has the potential to replace up to 30 primary cells.
|Plasma Antennas - Investment Information for OT2|
|Date of First Investment||Nov 2001|
|Plasma Antennas - Investment Information for OT3|
|Date of First Investment||Sep 2004|
|Plasma Antennas - Investment Information for OT4|
|Date of First Investment||Mar 2005|
Plasma Antennas has developed a range of next-generation smart selectable multi-beam antenna technologies for small cell backhaul, broadband wireless access, mesh network and other communications and sensing applications. Based on a set of patented beamforming technologies, these high-performance electronically-steerable antennas are extremely lightweight and compact.
|Scancell- Investment Information for OT1|
|Date of First Investment||Aug 1999|
|Scancell- Investment Information for OT3|
|Date of First Investment||Dec 2003|
|Scancell- Investment Information for OT2|
|Date of First Investment||April 2018|
Scancell is an AIM listed biotechnology company in which Oxford Technology VCT was one of the original investors in 1999 when Professor Lindy Durrant, Scancell’s founder was based in a university lab in Nottingham.
Scancell is developing novel immunotherapies for cancer based on two platform technologies, known as ImmunoBody and Moditope. Scancell’s first ImmunoBody, SCIB1 is being developed for the treatment of melanoma and is in Phase II clinical trials. In theory, these Scancell technologies could be used to treat many common forms of cancer, including breast and prostate. Data from the trials to date is encouraging and demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
Scancell remains a high risk investment – clinical trials can go either way, but if the trials go well, we would expect to see a significant increase in the share price. The whole area of cancer immunology is now centre stage for major pharmaceutical companies seeking to secure a long term position, as this very new exciting area starts to deliver excellent clinical outcomes, which are anticipated to replace current crude, but often effective, treatments based around chemotherapy and radiotherapy.
New data published in March 2015 demonstrated that animals treated with a combination of SCIB2, Scancell's ImmunoBody® vaccine in development for the treatment of lung, oesophageal, prostate and other epithelial cancers, and checkpoint inhibition showed enhanced tumour destruction and significantly longer survival times than when either treatment was used alone which is positive news.
Scancell Holdings is listed in the FTSE AIM All-Share Index in the Pharmaceuticals & Biotechnology sector. (Code SCLP)
|Select Technology- Investment Information for OT1|
|Date of First Investment||Sep 1999|
|Select Technology- Investment Information for OT2|
|Date of First Investment||Nov 2001|
|Select Technology- Investment Information for OT3|
|Date of First Investment||Nov 2004|
|Select Technology- Investment Information for OT4|
|Date of First Investment||Aug 2006|
Select Technology (STL Management Ltd) distributes high quality document management software via its global channel partners while adding significant further value through its development team by providing integrations or bespoke solutions. Select Technology grew significantly between 2010 and 2018 by focusing on print management software, primarily PaperCut. Realising that this type of software has become increasingly commoditised, the company changed its focus to document capture and sharing, acquiring distribution rights to additional software solutions and introducing them to the market in an innovative way.
Select Technology has also been a leading light in the formation of IDEA – the International Document Evolution Alliance. The founder members of the Alliance are all software specialists and able to provide a very high level of support for the products which they distribute. Each member is located in a separate geographical region and, between them, the members cover over 100 countries. This allows members to compete with major companies in attracting international business which, individually, they would not be able to do.
In addition, if an Alliance member encounters a new product for the document management market with significant potential, the member can bring it to the attention of IDEA. Given the combined purchasing power and expertise of the group, the Alliance can look to negotiate international distribution rights by offering the vendor an easy route to global distribution. The products which Select Technology distributes include Drivve Image, Everyone Print, Foldr, KPAX Management, Papercut and Square 9 content management.
Share Price Information and RNS Announcements
For information from the London Stock Exchange on the share price for OT2 and all RNS announcements, please click on the image below:
Venture Capital Trust
Annual Statements & Interim Statements
Adobe Acrobat Reader is required to view these files, which can be downloaded from www.adobe.com
Annual Statements [Year to 28 February]
OT2 Annual Statement 2021 OT2 Annual Statement 2020 OT2 Annual Statement 2019 OT2 Annual Statement 2018 OT2 Annual Statement 2017 OT2 Annual Statement 2016 OT2 Annual Statement 2015 OT2 Annual Statement 2014 OT2 Annual Statement 2013 OT2 Annual Statement 2012 OT2 Annual Statement 2011 OT2 Annual Statement 2010 OT2 Annual Statement 2009 OT2 Annual Statement 2008 OT2 Annual Statement 2007 OT2 Annual Statement 2006 OT2 Annual Statement 2005 OT2 Annual Statement 2004 OT2 Annual Statement 2003 OT2 Annual Statement 2002 OT2 Annual Statement 2001
Interim Statements [6 months to 31 August]
OT2 Interim Statement 2021 OT2 Interim Statement 2020 OT2 Interim Statement 2019 OT2 Interim Statement 2018 OT2 Interim Statement 2017 OT2 Interim Statement 2016 OT2 Interim Statement 2015 OT2 Interim Statement 2014 OT2 Interim Statement 2013 OT2 Interim Statement 2012 OT2 Interim Statement 2011 OT2 Interim Statement 2010 OT2 Interim Statement 200 OT2 Interim Statement 2008 OT2 Interim Statement 2007 OT2 Interim Statement 2006 OT2 Interim Statement 2005 OT2 Interim Statement 2004 OT2 Interim Statement 2003 OT2 Interim Statement 2001 OT2 Interim Statement 2000